NP2
Phase 1Biologic
NP2 is one of 43 biologic programs targeting Cancer Pain. It is currently in Phase 1.
1
Indications
2
Total Trials
0
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
94 competitors in Cancer Pain
#DrugCompanyPhaseTrials
1MS Contin
Merck & Co.Phase 3
Medrol
PfizerPhase 3
Ketalar
AAultman Health Foundation
Phase 3
Xylocaine
MMEDRx USA, Inc.
Phase 3
Advil
KKenvue Brands
Phase 3
Ultram
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Narcan
SScienture
Phase 3
OROS Oxybutynin
Johnson & JohnsonPhase 3
Oxycodone CR
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Nacl
BayerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NP2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- DDiamyd Inc